| Literature DB >> 32313187 |
Cheng-Yu Long1,2, Chiu-Lin Wang1,2, Kun-Ling Lin3, Chin-Ru Ker2, Zixi Loo3, Yiyin Liu1, Pei-Chi Wu4.
Abstract
We aim to assess the surgical outcomes of our novel hysteropexy procedure, laparoscopic long mesh surgery (LLMS) with augmented round ligaments. Twenty-five consecutive women with stage II or greater main uterine prolapse defined by the POP quantification staging system were referred for LLMS. Long mesh is a synthetic T-shaped mesh, with the body fixed at the uterine cervix and the two arms fixed along the bilateral round ligaments. The clinical evaluations performed before and 6 months after surgery included pelvic examinations, urodynamic studies, and questionnaires for urinary and sexual symptoms. After a follow-up time of 12 to 24 months, the anatomical reduction rate was 92% (23/25) for the apical compartment. The average operative time was 65.4 ± 28.8 minutes. No major complications were recognized during LLMS. The lower urinary tract symptoms and scores on the questionnaires improved significantly after the surgery, except urgency urinary incontinence and nocturia. Neither voiding nor storage dysfunction was observed after the operations. All of the domains and total Female Sexual Function Index (FSFI) scores of the 15 sexually active women did not differ significantly after LLMS. The results of our study suggest that LLMS is an effective, safe, and time-saving hysteropexy surgery for the treatment of apical prolapse.Entities:
Mesh:
Year: 2020 PMID: 32313187 PMCID: PMC7171133 DOI: 10.1038/s41598-020-63725-x
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Demographic characteristics of the women who received laparoscopic long mesh surgery with augmented round ligaments (n = 25).
| Parameters | mean± SD n (%) |
|---|---|
| Age (years) | 55.3 ± 10.8 |
| Parity | 1.9 ± 0.5 |
| BMI (kg/m2) | 24.0 ± 3.2 |
| Menopause | 17 (68) |
| Current hormone therapy | 1 (4) |
| Diabetes mellitus | 1 (4) |
| Hypertension | 8 (32) |
| Baseline apical stage II POP | 11 (44) |
| with anterior stage II POP | 4 (16) |
| with anterior stage III POP | 3 (12) |
| with posterior stage II POP | 1 (4) |
| Baseline apical stage III POP | 14 (56) |
| with anterior stage III POP | 3 (12) |
| with posterior stage II POP | 2 (8) |
| Concomitant procedures in this study | |
| Anterior colporrhaphy | 3 (12) |
| Posterior colporrhaphy | 3 (12) |
| Cervical amputation | 9 (36) |
| Myomectomy | 2 (8) |
| Midurethral sling | 3 (12) |
| Follow-up (months) | 12–24 |
†Data are given as the mean ± standard deviation or n (%).
‡BMI: body mass index; POP: pelvic organ prolapse.
Pelvic organ prolapse quantification (POP-Q) values before and after surgery.
| POP-Q parameters | Preoperative (n = 25) | Postoperative (n = 25) | |
|---|---|---|---|
| Aa | 0 (−3~1.5) | −2 (−3~−1) | <0.001 |
| Ba | 2.5 (−0~3) | −2 (−3~−1) | <0.001 |
| C | 2.5 (−3~3) | −8 (−6~−10) | <0.001 |
| Ap | −2 (−3~−2) | −3 (−3~−2) | 0.030 |
| Bp | 1 (−3~2) | −2 (−3~−1) | 0.002 |
| TvL | 9 (9~11) | 9 (9~10) | 0.521 |
| Recurrent POP | |||
| Apical prolapse | 2 (8) | ||
| Anterior vaginal prolapse | 1 (4) | ||
| Posterior vaginal prolapse | 0 | ||
*The Wilcoxon signed-rank test.
†Data are given as the median (range) or n (%).
Urinary symptoms and quality of life questionnaires before and 6 months after surgery.
| Symptoms | Preoperative (n = 25) | Postoperative (n = 25) | |
|---|---|---|---|
| Urinary frequency | 9 (36) | 1 (4) | 0.021*** |
| Stress urinary incontinence | 20 (80) | 6 (24) | <0.001*** |
| Urgency urinary incontinence | 6 (24) | 2 (8) | 0.22 *** |
| Feeling of incomplete bladder emptying | 14 (56) | 2 (8) | <0.001*** |
| Hesitancy | 13 (52) | 4 (16) | 0.004*** |
| Nocturia | 18 (72) | 13 (52) | 0.27 *** |
| OABSS | 4.8 ± 3.3 | 3.9 ± 1.8 | 0.004*** |
| UDI-6 | 25.1 ± 16.8 | 14.4 ± 6.8 | 0.009*** |
| IIQ-7 | 32.4 ± 24.3 | 13.3 ± 12.8 | <0.001*** |
| POPDI-6 | 9.2 ± 4.8 | 5.5 ± 3.0 | <0.001*** |
*McNemar’s test.
**Fisher’s exact test.
***Paired t-test.
†Data are given as the mean ± standard deviation or n (%).
‡Pre-op, preoperative; post-op, postoperative; OABSS, overactive bladder symptom score; UDI-6, Urogenital Distress Inventory; IIQ-7, the Incontinence Impact Questionnaire; POPDI-6, pelvic organ prolapse distress inventory 6.
Urodynamic changes before and 6 months after surgery.
| Parameters | Preoperative (n = 25) | Postoperative (n = 25) | |
|---|---|---|---|
| Qmax (mL/s) | 19.4 ± 6.7 | 18.8 ± 4.0 | 0.71** |
| RU (mL) | 31.0 ± 14.5 | 11.2 ± 5.7 | 0.006** |
| DO | 8 (32) | 3 (12) | 0.70** |
| FS (mL) | 157.7 ± 49.5 | 154.5 ± 62.3 | 0.63** |
| MCC (mL) | 287.2 ± 79.4 | 311.0 ± 59.5 | 0.07** |
| PdetQmax (cmH2O) | 24.5 ± 12.9 | 23.0 ± 15.9 | 0.52** |
| FUL (mm) | 28.4 ± 5.4 | 29.4 ± 6.8 | 0.82** |
| MUCP (cmH2O) | 52.3 ± 21.2 | 54.1 ± 20.7 | 0.75** |
*Fisher’s exact test.
**Paired t-test.
†Data are given as the mean ± standard deviation or n (%).
‡Pre-op, preoperative; post-op, postoperative; Qmax, maximum flow rate; RU, residual urine; DO, detrusor overactivity; FS, first sensation to void; MCC, maximum cystometric capacity; PdetQmax, detrusor pressure at peak flow; FUL, functional urethral length; MUCP, maximum urethral closure pressure.
Changes in scores of the Female Sexual Function Index before and 6 months after surgery.
| Parameters | Preoperative (n = 15) | Postoperative (n = 15) | |
|---|---|---|---|
| Sexual desire | 3.5 ± 0.5 | 3.6 ± 0.8 | 0.77 |
| Sexual arousal | 3.9 ± 0.9 | 3.8 ± 0.6 | 0.48 |
| Lubrication | 4.5 ± 0.8 | 4.1 ± 1.3 | 0.27 |
| Orgasm | 4.7 ± 0.9 | 4.3 ± 0.5 | 0.12 |
| Satisfaction | 4.8 ± 0.9 | 4.9 ± 0.8 | 0.16 |
| Dyspareunia | 4.9 ± 1.3 | 4.1 ± 1.3 | 0.12 |
| Total scores | 26.3 ± 4.6 | 24.8 ± 3.0 | 0.19 |
*Paired t-test.
†Data are given as the mean ± standard deviation.
Intraoperative and postoperative complications.
| n = 25 | Clavien-Dindo Classification | |
|---|---|---|
| Operative time (minutes) | 65.4 ± 28.8 | |
| Intraoperative complications | ||
| Bladder injury | 0 | |
| Rectal injury | 0 | |
| Blood transfusion | 0 | |
| Conversion to open surgery | 0 | |
| Postoperative complications | ||
| Postoperative day 1 VAS score | 2.1 ± 1.5 | Grade I |
| Urinary tract infection | 3 (12) | Grade II |
| Voiding dysfunction | 0 | |
| Pelvic hematoma | 0 | |
†Data are given as the mean ± standard deviation or n (%).
‡VAS, visual analogue scale.
Figure 1The clinical trial flowchart for laparoscopic long mesh surgery with augmented round ligaments.
Figure 2The parameters and design of the long mesh.
Figure 3The procedural process. (A) Under laparoscopy, the peritoneum of the utero-vesical fold was dissected to expose the anterior colpo-cervical junction. T-shaped self-tailored long mesh was delivered to the operation field. Bilateral mesh legs were extracted outside the trocar wounds to stabilize the mesh position. (B) Center piece of the mesh was fixed to the cervix with ProTack screws (Covidien, New Haven, Connecticut), Stratafix 2-0 sutures (Ethicon, Norderstedt, Germany) and Tisseel fibrin sealant (Baxter, Deerfield Illinois). (C) Bilateral round ligaments and the mesh arms were sutured continuously with Stratafix 2-0. (D) Reperitonealization with the remaining Stratafix 2-0 sutures. (E) The tension of the mesh was adjusted until the cervix was reduced to the deepest point according to the vaginal examination.